Drug intelligence / Profile preview

MicroRNA-101

Development stage
Preclinical
Modality
RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Oral, Intravenous, Subcutaneous
01

Overview

MicroRNA-101 (miR-101) is a non-coding RNA that plays a crucial role in cartilage development and destruction. It epigenetically regulates integrin-α1 expression by targeting DNA methyltransferase 3B (DNMT-3B). Upregulation of miR-101 leads to the inhibition of DNMT-3B, which in turn alters the methylation of integrin-α1, a positive regulator of endochondral ossification. Conversely, downregulation of miR-101 results in increased DNMT-3B and decreased integrin-α1, contributing to cartilage destruction. Preclinical studies have shown that introducing miR-101 via lentiviruses can reduce cartilage destruction in animal models of osteoarthritis, suggesting its potential as a therapeutic target for cartilage-related diseases.

02

Targets

DNMT3A (DNA methyltransferase 3 alpha)EZH2 (Histone-lysine N-methyltransferase EZH2)Proto-oncogene c-Fos messenger RNADNMT3B (DNA (cytosine-5)-methyltransferase 3B)ITGA1 (Integrin Subunit Alpha 1)

Beyond the preview

Go deeper on MicroRNA-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroRNA-101.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call